Canada Markets close in 4 hrs 41 mins

Soligenix, Inc. (SNGX)

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
Add to watchlist
0.8000+0.0198 (+2.54%)
As of 04:00PM EST. Market open.
Full screen
Trade prices are not sourced from all markets
Previous Close0.7802
Open0.7788
Bid0.7734 x 3000
Ask0.8000 x 800
Day's Range0.7500 - 0.8180
52 Week Range0.7500 - 2.8000
Volume400,799
Avg. Volume1,740,530
Market Cap32.063M
Beta (5Y Monthly)1.30
PE Ratio (TTM)N/A
EPS (TTM)-0.4040
Earnings DateNov. 10, 2021 - Nov. 15, 2021
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est4.88
  • Newsfile

    Soligenix Proof of Concept Uncovers Potential Treatment Option for the World's 125 Million Psoriasis Sufferers

    New York, New York--(Newsfile Corp. - November 30, 2021) - PCG Digital -- Proof of concept in the biopharmaceutical sector is a process. Efficacy tests are performed, results are recorded from each round of clinical trials, and formulation changes are made if necessary. Each iteration moves the treatment closer to an NDA filing, with an end goal of achieving FDA approval. The goal is to gather enough data during trials to make that happen. ...

  • Newsfile

    Highlights and Insights into Soligenix

    Dr. Chris Schaber Discusses Soligenix HyBryte(TM) and Thermostabilized Vaccines New York, New York--(Newsfile Corp. - October 13, 2021) - PCG Digital -- In a recent interview with Kristen Kluska, a biotechnology analyst at Cantor, Dr. Chris Schaber, President and CEO of Soligenix (NASDAQ: SNGX), spoke about the latest developments with their synthetic hypericin topical treatment HyBryte™ and the Company's ongoing research and development of thermostabilized vaccine candidates for filoviruses and

  • Newsfile

    Vaccine from Soligenix Could Accelerate Global Recovery from COVID-19 Pandemic

    COVID-19 Vaccine Candidate Demonstrates Broad Neutralizing Antibody Response Against Beta, Gamma and Delta Variants New York, New York--(Newsfile Corp. - October 7, 2021) - PCG Digital -- Shipping and administering COVID-19 vaccines that need to be stored at sub-zero temperatures is hampering the pandemic recovery efforts of health professionals around the world. Soligenix, Inc (NASDAQ: SNGX), a US-based late-stage biopharmaceutical company, is developing a solution to that problem. The Company